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Abstract
The present study characterized the behavioral mechanisms of avoidance–disruptive effect of quetiapine in the conditioned avoidance response test under two behavioral testing (2 warning signals vs. 1 warning signal) and two drug administration conditions
(subcutaneous vs. intravenous). In Experiments 1 and 2, well-trained adult male Sprague-Dawley rats were tested under the subcutaneous (s.c.) quetiapine treatment (5.0, 15.0, 25.0, 50.0 mg/kg) for 7 days in a novel procedure consisting of two conditioned stimuli (CS) (white noise serving as CS1 and pure tone as CS2). Only the highest dose (50.0 mg/kg) produced a persistent suppression
of the avoidance response without impairing the escape response. The magnitude of suppression of the CS1 avoidance was similar
to that of CS2 avoidance. No significant group difference was found in the quetiapine (15.0 mg/kg, s.c.) challenge test, indicating a
lack of a long-term quetiapine effect. In Experiment 3, well-trained rats were tested under the intravenous (i.v.) quetiapine treatment
(3.0, 9.0, 15.0 mg/kg) for 5 days and challenged with quetiapine (6.0 mg/kg, i.v. followed by 9.0 mg/kg, s.c.). Only the white noise was
used as the CS. Similar to what was being observed in Experiments 1 and 2, intravenously administered quetiapine dose-dependently suppressed avoidance responding during the drug test days, but did not alter drug sensitivity in the challenge days. Thus, quetiapine does not appear to show a preferential inhibition of the avoidance response to a less salient stimulus; and prior quetiapine
treatment (s.c. and i.v.) does not cause a sensitization or tolerance to quetiapine.
Keywords: Quetiapine, CS1 and CS2, Conditioned avoidance response, Sensitization, Tolerance
1. Introduction

that the avoidance–disruptive effect of haloperidol, olanzapine and
clozapine can be potentiated by the increase in number of CS trials in the test sessions (Feng et al., 2012; Li et al., 2007). Furthermore, both clozapine and olanzapine show a greater suppression
of the avoidance response to a less salient CS than to a more salient CS (Li et al., 2009b, 2012; Zhang et al., 2011). We also identified another behavioral mechanism which relates to the druginduced alteration of drug sensitivity. We showed that repeated
treatment with haloperidol, olanzapine or risperidone daily for 5–7
days tends to cause a progressively increased inhibition of avoidance responding (a sensitization effect), while repeated administration of clozapine causes a decreased inhibition upon repeated administration (a tolerance effect) (Feng et al., 2013b; Li et al., 2010,
2012; Qiao et al., 2013). These findings are consistent with earlier
studies showing that the anti-avoidance effect of haloperidol is

The conditioned avoidance response model (CAR) is a classic behavioral screening tool for chemical compounds with antipsychotic
activity, as avoidance suppression is a common and distinct property of antipsychotic drugs but not that of other psychotropic
drugs. This task is also useful for the study of the behavioral mechanisms of antipsychotic action (Li et al., 2007, 2009a, 2009b, 2004,
2010, 2012; Mead and Li, 2010; Swalve and Li, 2012). In this regard,
we have shown that antipsychotic drugs suppress avoidance response by attenuating the motivational salience of a conditioned
stimulus (CS) to elicit avoidance response. The attenuation action
on the motivational salience of the CS refers to the weakening effect of antipsychotic treatment on the ability of the CS to instigate
an active motor response from an organism. We demonstrated
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progressively enhanced with each subsequent drug administration (Fregnan and Chieli, 1980), while that of clozapine is progressively decreased (Sanger, 1985).
The present study was designed to examine the behavioral
mechanisms of action of quetiapine in the CAR model. Specifically,
we attempted to determine whether quetiapine disrupts avoidance
response by attenuating the motivational salience of the CS and
induces a long-term change in drug sensitivity (either sensitization
or tolerance). Quetiapine is a widely used atypical antipsychotic
drug that is effective in the treatment of schizophrenia, bipolar
disorders and other mental disorders (Zhornitsky et al., 2011). It is
also used as an adjuvant treatment for major depressive disorder
and those who did not have an adequate response to antidepressant therapy (Bandelow et al., 2014; Sanford, 2011). Although its
avoidance disruptive effect has been demonstrated before (Bjorkholm et al., 2013; Wadenberg et al., 2001), how quetiapine disrupts
avoidance response and what kind of behavioral pattern (sensitization or tolerance) it would induce has never been studied. Since
quetiapine exhibits clozapine-like lower levels of dopamine D2 receptor occupancy (less than 70%) at therapeutically effective doses
and a clozapine-like fast dissociation from the D2 receptor (Kapur
and Seeman, 2000; Kapur et al., 2000), we hypothesized that repeated treatment of quetiapine would cause a clozapine-like tolerance effect (as opposed to olanzapine-like sensitization) in the
CAR model. To examine its potential action on the motivational salience of the CS, we tested quetiapine in a modified CAR paradigm
involving two types of CS signals with different levels of motivational salience (Li et al., 2009b, 2012, Zhang et al., 2011).
2. Materials and methods
2.1. Animals
In Experiment 1, 50 adult male drug-naive Sprague-Dawley rats
(226–250 g upon arrival, Charles River, Portage, MI) were used
as subjects. In Experiment 2, 40 adult Sprague-Dawley rats (226–
250 g upon arrival) that had been previously used in another study
were used. These rats had been repeatedly injected with saline,
nicotine 0.2 mg/kg, or nicotine 0.4 mg/kg, in combination with
saline or phencyclidine (2.0 mg/kg) for 7 days, and tested for the
ultrasonic vocalization under PCP and/or nicotine. However, none
of them had any experience with quetiapine. We used them in this
study in an attempt to replicate findings from Experiment 1. Because they had different drug experience compared to rats used
in Experiment 1, the consistent findings from both experiments
would enhance the confidence of our findings. In Experiment 3,
46 adult male drug-naive Sprague-Dawley rats (226–250 g upon
arrival) were used. Rats were housed two per cage, in transparent
polycarbonate cages (48.3 × 26.7 × 20.3 cm) under 12-hr light/
dark conditions (light on between 6:30 a.m. and 6:30 p.m.). Room
temperature was maintained at 22±1 °C with a relative humidity
of 45–60%. Food and water was available ad libitum. Animals were
allowed at least 5 days of habituation to the animal facility before
being used in experiments. All experiments were performed during the light cycle and all procedures were approved by the Institutional Animal Care and Use Committee at the University of
Nebraska–Lincoln.
2.2. Drugs
Quetiapine fumarate (QUE, a gift from the National Institute of
Mental Health drug supply program) was dissolved in a minimal
amount (up to 1.5%) of glacial acetic acid and made up to volume
with distilled sterile water (Kapur et al., 2003 and Wadenberg et al.,
2001), and injected subcutaneously (s.c., 1.0 ml/kg) in Experiments
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1 and 2. For Experiment 3, QUE was dissolved in a minimal amount
of acetic acid (up to 1%) and diluted to the appropriate concentration with saline (0.9% NaCl solution), the pH was raised slightly
by adding of a few drops of 1 N NaOH and injected intravenously
(i.v., 1.0 ml/kg) into a lateral tail vein (Bjorkholm et al., 2013). We
tested a wide range of QUE doses (3–50 mg/kg) to assess the possible dose-dependent nature of QUE effects. QUE is shown to suppress avoidance response at >20 mg/kg s.c. and >6.0 mg/kg i.v.
(Bjorkholm et al., 2013 and Wadenberg et al., 2001).
2.3. Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med Associates (St. Albans, VT) were used. Each
box was housed in a ventilated, sound-insulated isolation cubicle
(96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm long,
30 cm high (from grid floor), and 24 cm wide, and was divided
into two equal-sized compartments by a partition with an arch
style doorway (15 cm high × 9 cm wide at base). A barrier (4 cm
high) was placed between the two compartments, so the rats had
to jump from one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a diameter of 0.48 cm, spaced
1.6 cm apart center to center, through which a scrambled footshock (unconditioned stimulus, US, 0.8 mA,) was delivered by a
constant current shock generator (Model ENV-410B) and scrambler (Model ENV-412). The rat location and crossings between
compartments were monitored by a set of 16 photobeams (ENV256-8P) affixed at the bottom of the box (3.5 cm above the grid
floor). Illumination was provided by two houselights mounted at
the top of each compartment. The auditory stimuli were generated
by a programmable audio generator (ANL-926) and delivered by
the speaker (ENV-224AM). In Experiments 1 and 2, a 76 dB white
noise (the sound frequency ranged from 10 to 35,000 Hz in 1 Hz
increment, serving as CS1) and an 85 dB 2800 Hz pure tone (serving as CS2) were used. In Experiment 3, only the white noise was
used. Both sounds were produced by a speaker (ENV 224 AMX)
mounted on the ceiling of the cubicle, centered above the shuttle
box. Background noise (approximately 74 dB) was provided by a
ventilation fan affixed at the top corner of each isolation cubicle.
All training and testing procedures were controlled by Med Associates programs running on a computer.
2.4. Experiment 1: Effect of repeated QUE treatments on CS1 and
CS2 avoidance in normal rats
Fifty rats were first handled and habituated to the CAR boxes for 2
days (20 min/day), and then trained to make avoidance responses
to the white noise (CS1) for a total of 10 days/sessions over a
2-week period. Each session consisted of 30 trials, with inter-trial
intervals randomly varying between 30 and 60 s. Every trial started
with the presentation of white noise for 10 s, followed by a continuous scrambled foot shock (0.8 mA, US, maximum duration =
5 s) on the grid floor. An avoidance response was registered if a
rat crossed from one compartment into the other within the 10 s
of CS1 presentation. An escape was registered if the rat remained
in the same compartment for more than 10 s and made a crossing
only after receiving the footshock. If the rat did not switch compartments during the entire 5 s presentation of the shock, the trial
was terminated and the inter-trial interval started.
At the end of the training session, 42 rats reached the training criterion (>70% CS1 avoidance in each of the last 2 sessions).
They were first matched on avoidance performance on the last
training day (pre-drug) to create blocks of rats that were approximately equal in performance. Within each block, they were
then randomly assigned to 1 of 5 groups: QUE 5.0 mg/kg (n=8),
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QUE 15.0 mg/kg (n=8), QUE 25.0 mg/kg (n=10), QUE 50.0 mg/
kg (n=8), and vehicle (n=8), and tested daily in a modified avoidance response test procedure for 7 consecutive days. On each
test day, rats were first injected with QUE or vehicle (sterile water), and tested 1 h later. Each test session consisted of 30 trials
with 20 CS1 trials intermixed with 10 CS2 (pure tone) trials. The
CS1 trials were identical to the trials used in the training phase.
The 10 CS2 trials used a pure tone (10 s, 2800 Hz, 85 dB) as the
signal with its termination immediately followed by the shock if
the rats did not make an avoidance response ( Li et al., 2009b, Li
et al., 2012 and Zhang et al., 2011). This modified avoidance test
procedure provides a condition to delineate the strength of the
avoidance disruptive effect of QUE.
One day after the last CAR drug test, all rats were retrained
drug-free under the CS-only condition (20 CS1 trails and 10 CS2
trials) for one session, and under the CS–US condition (20 CS1
trails and 10 CS2 trials) for another session to bring their avoidance back to the pre-drug level. A final challenge test was conducted 24 h later during which all rats were injected with QUE
15.0 mg/kg, and 1 h later, tested for avoidance performance under the CS-only condition (20 CS1 trails and 10 CS2 trials), as previously employed (Li et al., 2012). Table 1 summarizes the experimental procedure.
2.5. Experiment 2: effect of repeated QUE treatments on CS1 and
CS2 avoidance in nicotine and PCP pretreated rats
In this experiment, we replicated Experiment 1 by testing QUE in
40 rats that were previously treated with nicotine and PCP. The
PCP-pretreated rats were used here as “diseased” rats, as PCP is
commonly used to induce changes resembling schizophrenia at
multiple levels, such as abnormality of glutamatergic neurotransmission and neurodevelopment (Mouri et al., 2007), neuropsychological deficits (Javitt and Zukin, 1991), and prepulse inhibition deficit (Geyer et al., 2001). Our previous study showed that
this PCP treatment regimen does cause a disruption of PPI (Li et
al., 2011), thus, this experiment extended the study of QUE’s antipsychotic effects in normal rats to rats with schizophrenia-like
symptoms. Rats were first trained to acquire CS1 avoidance responding for 10 sessions. At the end of the training phase, 34 rats
had reached the training criterion (>70% avoidance in each of the
last 2 sessions). They were then semi-randomly assigned to 1 of 5
groups (matched by their avoidance performance and their previous experience with nicotine and PCP): QUE 5.0 mg/kg (n = 6),
QUE 15.0 mg/kg (n = 7), QUE 25.0 mg/kg (n = 6), QUE 50.0 mg/

kg (n = 8), and vehicle (n = 7). The remainder of the experimental
procedure was identical to that of Experiment 1.
2.6. Experiment 3: effect of repeated QUE treatments (i.v.) on conditioned avoidance in normal rats
To circumvent the first-pass metabolism (Pond and Tozer, 1984)
and skin lesions produced by s.c. injection, we used the intravenous route of administration in this experiment. This change in injection route would provide a more complete picture of the behavioral effects of QUE. In this experiment, 46 rats were trained
in the same procedure as those in the previous experiments. At
the end of the training session, 36 rats acquired a robust avoidance responding (≥70% avoidance in each of the last 2 sessions).
They were matched on the level of avoidance and then randomly
assigned into 4 groups (n = 8–10/group): vehicle (n = 9), QUE
3.0 mg/kg (n = 9), QUE 9.0 mg/kg (n = 8), QUE 15.0 mg/kg (n =
10). They were then tested daily under the CS (white noise)-only
condition (no shock, 30 trials/session) for 5 consecutive days. This
procedure has been routinely used in our studies of antipsychotic
sensitization and tolerance ( Feng et al., 2013a, Feng et al., 2013b,
Gao and Li, 2013, Gao et al., 2015, Swalve and Li, 2012 and Zhang
and Li, 2012). On each test day, rats were first injected with vehicle (VEH) or QUE in a lateral tail vein (i.v.) and tested in the CAR
boxes 20 min later. One day after the last (5th) drug test day, all
rats were retrained drug-free for 1 session under the CS-only (no
shock) condition, followed by another under the CS–US condition
to bring their avoidance responses back to the pre-drug level. On
the challenge day, all rats were injected with QUE at 6. 0 mg/kg
(i.v.) and tested for avoidance performance in the CS-only condition (30 trials) 20 min later. One day after this challenge test,
all rats were once again retrained for 2 sessions (1 under the CSonly and 1 under the CS–US condition), followed by another QUE
(9.0 mg/kg, s.c.) challenge test 1 day later (see Table 1).
2.7. Statistical analysis
Avoidance and escape performance was expressed as the mean
percent+S.E.M. (i.e. number of avoidance or escape response/total
number of trials). Avoidance data from the repeated drug test days
and the challenge test were analyzed using a split-plot analysis of
variance (ANOVA) with the between-subjects factor of drug group,
and the within-subjects factor of test day and CS condition (CS1 or
CS2) (only for Experiments 1 and 2). Escape data was similarly analyzed with the exception of no CS condition as a within-subject

Table 1. A schematic depiction of the experimental procedures used in Experiments 1, 2 and 3. QUE: quetiapine; CS: conditioned stimulus; US: unconditioned stimulus.

Repeated quetiapine treatment & conditioned avoidance responding in rats

157

Figure 1. Effect of repeated subcutaneous administration of quetiapine (5, 15, 25 and 50 mg/kg, sc, −60 min) on CS1 – (A) and CS2 (B) – elicited
avoidance response and escape response (C) during the 7 drug test days, and its effect on the CS1 – (D) and CS2 – (E) avoidance response on the
quetiapine challenge day (quetiapine 15 mg/kg, s.c.) in normal rats. Percentages of avoidance or escape response (mean+S.E.M.) made by normal
rats in the 5 groups on the last training day (pre-drug) and during the 7 drug test days, on the last retraining (drug-free) day and the quetiapine challenge day are shown. *P<0.05 in comparison to the vehicle group.

factor. One-way ANOVAs followed by post-hoc LSD tests were
used to compare group differences on specific drug test days and
challenge days. For all comparisons, significant difference was assumed at P<0.05, and all data was analyzed using SPSS version 21.
3. Results
3.1. Experiment 1: Effect of repeated subcutaneous administration
of QUE on CS1 and CS2 avoidance in normal rats
3.1.1. Avoidance response during the drug treatment days
Figure 1(A and B) shows the mean percentage of CS1 avoidance (A) and CS2 avoidance (B) on the last training (pre-drug)
day and throughout the 7 drug test days. On the pre-drug day,
there were no significant group differences [F(4,37) = 0.952, P =
0.445]. Throughout the QUE test phase, rats made a higher percentage of CS1 avoidances than CS2 avoidances. Only QUE 50 mg/
kg showed an apparent disruption of avoidance responses. A splitplot ANOVA indicated a main effect of group [F(4,37) = 3.645, P =
0.013], a main effect of CS condition [F(1,37) = 262.331, P<0.001],
but no main effect of day [F(6,222) = 1.296, P = 0.260], nor any
significant interactions (all P>0.284). Post-hoc Fisher’s LSD tests
showed that the QUE 50 group had significant lower avoidance
than the vehicle group (P = 0.003). It also had significantly lower
avoidance than other QUE groups (all P<0.007) except the QUE 25

group (P = 0.075). One-way ANOVAs followed by post-hoc Fisher’s LSD tests on each test day revealed that the QUE 50 group
had significantly lower CS1 avoidance percentages than the VEH
group on day 2, P = 0.002, day 5, P = 0.002, day 6, P = 0.011, and
day 7, P = 0.008; and significantly lower CS2 avoidance percentage
than the VEH group on day 2, P = 0.017 ( Figure 1B). These findings demonstrated that only the high-dose of QUE (50.0 mg/kg)
was able to cause a persistent suppression of avoidance responses
to CS1 (less to CS2) across the drug test sessions.
3.1.2. Escape response during the drug treatment days
Figure 1C shows the mean percentage of total escape responses
on the last training (pre-drug) day and throughout the 7 drug
test days. On the pre-drug day, there were no significant group
differences [F(4,37) = 1.129, P = 0.358]. A split-plot ANOVA indicated that throughout the QUE test phase, there was no main effect of day [F(6,222) = 1.252, P = 0.281], group [F(4,37) = 1.950, P
= 0.123], nor a significant interaction between the two [F(24,222)
= 0.853, P = 0.666].
3.1.3. Avoidance response on the challenge test
Figure 1(D and E) shows the mean percentage of CS1 and CS2
avoidance responses on the last retraining (drug-free) day and the
QUE challenge day. On the retraining day, rats in different groups
all had a higher level of avoidance responding to the CS1 than to
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Figure 2. Effect of repeated subcutaneous administration of quetiapine (5, 15, 25 and 50 mg/kg, sc, −60 min) on CS1 – (A) and CS2 (B) – elicited avoidance response, escape response (C) during the 7 drug test days, and its effect on the CS1 – (D) and CS2 – (E) avoidance response on the quetiapine
challenge day (quetiapine 15 mg/kg, s.c.) in nicotine and phencyclidine pretreated rats. Percentages of avoidance or escape response (mean+S.E.M.)
made by nicotine and phencyclidine pretreated rats in the 5 groups on the last training day and during the 7 drug test days, on the last retraining
(drug-free) day and the quetiapine challenge day are shown. *P<0.05 in comparison to the vehicle group.

the CS2, and there was no significant group difference. A split-plot
ANOVA showed a main effect of CS condition [F(1,37) = 68.300,
P<0.001], but no main effect of group [F(4,37) = 1.387, P = 0.257],
nor a CS condition × group interaction [F(4,37) = 1.421, P = 0.246].
On the challenge day, rats previously treated with various doses of
QUE for 7 days did not differ from those previously treated with
vehicle in both CS1 and CS2 avoidance. Two-way ANOVA showed
a main effect of CS condition [F(1,37) = 135.491, P<0.001], but no
main effect of group [F(4,37) = 0.866, P = 0.494], nor CS condition
× group interaction [F(4,37) = 1.086, P = 0.378].
3.2. Experiment 2: Effect of repeated subcutaneous administration
of QUE on CS1 and CS2 avoidance in nicotine and PCP pretreated
rats
3.2.1. Avoidance response during the drug treatment days
Figure 2(A and B) shows the mean percentage of CS1 avoidance
(A) and CS2 avoidance (B) on the last training (pre-drug) day and
during the 7 drug test days. There was no significant group difference on the pre-drug day [F(4,37) = 0.446, P = 0.774]. Throughout
the QUE test phase, only the QUE 50 group displayed significantly
lower percentages of CS1 and CS2 avoidance, especially towards
the end of the drug test phase. A split-plot ANOVA indicated a
main effect of group [F(4,29) = 4.520, P = 0.006], a main effect of
CS condition [F(1,29) = 180.803, P<0.001], and a significant day

× group interaction [F(24,174) = 1.812, P = 0.016]. There was no
main effect of day [F(6,174) = 1.460, P = 0.195], nor any other interactions (all ps>0.217). Post-hoc Fisher’s LSD tests showed the
QUE 50 group was significantly different from all other groups (all
p<0.023). One-way ANOVAs followed by post-hoc Fisher’s LSD
tests on each test day revealed that the QUE 50 group had significantly lower CS1 avoidance than the VEH group and other QUE
groups on the last 3 test days, all P<0.016, and significantly lower
CS2 avoidance on days 3–5 and day 7, all P<0.05.
3.2.2. Escape response during the drug treatment days
Figure 2C shows the mean percentage of escape response on the
last training (pre-drug) day and during the 7 drug test days. There
was no significant group difference on the pre-drug day [F(4,29)
= 0.257, P = 0.903]. In the QUE test phase, a split-plot ANOVA indicated a main effect of group [F(4,29) = 3.647, P = 0.016], but no
main effect of day [F(6,174) = 1.226, P = 0.295], nor a day × group
interaction [F(24,174) = 1.216, P = 0.234]. Post-hoc Fisher’s LSD
tests showed that the QUE 50 group had significantly higher escape percentages than the vehicle group (P = 0.015). It also had
significantly higher escape percentages than the other QUE groups
(all P<0.021) except the QUE 15 group (P = 0.153). One-way ANOVAs followed by post-hoc Fisher’s LSD tests on each test day revealed that the QUE 50 group had significantly more escapes than
the VEH group on the last 3 test days, all P<0.013, higher than the
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Figure 3. Effect of repeated intravenous administration of quetiapine (3, 9 and 15 mg/kg, i.v., −20 min) on conditioned avoidance response during the
5 drug test days (A) and the 2 drug challenge days (B: quetiapine 6 mg/kg, i.v.; C: quetiapine 9 mg/kg, s.c.). Percentages of avoidance (mean+S.E.M.)
made by normal rats in the 4 groups on the last training day (pre-drug) and during the 5 drug test days, on the last retraining (drug-free) day and
the quetiapine challenge day are shown. **P<0.01, ***P<0.001 in comparison to the vehicle group.

QUE 25 group on all days except day 1 and day 4, all P<0.008, and
higher than the QUE 5 group on days 2–3 and day 5, all P<0.026.
3.2.3. Avoidance response on the challenge test
Figure 2(D and E) shows the mean percentage of CS1 and CS2
avoidance responses on the last retraining (drug-free) day and the
QUE challenge day. Before the QUE challenge, rats showed significantly higher CS1 avoidance relative to CS2 avoidance, but there
was no significant group difference. There was a main effect of CS
condition [F(1,29) = 55.272, P<0.001], but no main effect of group
[F(4,29) = 1.100, P = 0.375], nor significant CS condition × group
interaction [F(4,29) = 1.652, P = 0.188]. On the challenge test, the
group differences were not apparent. A split-plot ANOVA showed
a main effect of CS condition [F(1,29) = 56.247, P<0.001], but no
main effect of group [F(4,29) = 1.241, P = 0.316], nor a significant CS condition × group interaction [F(4,29) = 1.023, P = 0.412].
3.3. Experiment 3: Effect of repeated intravenous administration of
QUE treatments on conditioned avoidance in normal rats
3.3.1. Avoidance response during the drug treatment days
Figure 3A shows the mean percentage of avoidance responses
on the last training (pre-drug) day and throughout the 5 drug
test days. On the pre-drug day, there was no significant group
difference [F(3,32) = 0.589, P = 0.627]. Throughout the QUE test
phase, QUE 9.0 and 15.0 mg/kg (i.v.) caused a strong suppression
of avoidance responding. A split-plot ANOVA revealed a main effect of group [F(3,32) = 30.367, P<0.001], but no main effect of
day [F(4,128) = 1.687, P = 0.157], nor any significant interaction
between the two [F(12,128) = 1.408, P = 0.170]. Post-hoc LSD
tests showed that all 3 QUE groups had significantly lower avoidance than the VEH group (QUE 3.0, P = 0.013; QUE 9.0 and 15.0,
both P<0.001). QUE 9.0 and 15.0 groups also had significantly
lower avoidance than the QUE 3.0 group (both P<0.001). Oneway ANOVA on each test day revealed that the QUE 9.0 and 15.0
groups had significantly lower avoidance than the VEH group on
all 5 days (all P<0.004), while the QUE 3.0 group showed lower
avoidance than the VEH group only on days 4 and 5 (P<0.001).
Additionally, QUE 9.0 and 15.0 groups have lower avoidance than
the QUE 3.0 groups on all 5 days (all P<0.045). These findings
indicate that QUE was able to dose-dependently cause a persistent suppression of the avoidance response across the drug
test sessions.

3.3.2. Avoidance response on the challenge test
Figure 3B shows the mean percentage of avoidance responses on
the 1st retraining day and the 1st QUE challenge day (6.0 mg/kg,
i.v.). No significant group difference was found [the 1st pre-drug
day, F(3,32) = 1.716, P = 0.183; the 1st challenge day, F(3,32) =
0.477, P = 0.700].
After 2 days of retraining, all rats were challenged again with
QUE (9.0 mg/kg, s.c.). As shown in Figure 3C, none of the groups
differed from each other on the 2nd retraining day [F(3,32) =
0.880, P = 0.462] or on the 2nd challenge day [F(3,32) = 0.434, P
= 0.730], indicating no long-term alteration of behavioral sensitivity to QUE after repeated intravenous QUE treatment.
4. Discussion
Using heterogeneous groups of rats (i.e. drug-naive and nicotine
and/or PCP treated rats), two CAR test procedures (CS1+CS2 vs.
CS1-only) and two drug administration routes (s.c. vs. i.v.), we demonstrated that under the subcutaneous administration condition,
only the high-dose of QUE (50 mg/kg) was able to cause a persistent and comparable suppression of avoidance responses to both
CS1 and CS2 during the repeated drug treatment phase (Experiments 1 and 2; Figure 1 and Figure 2). However, under the intravenous administration condition, all 3 doses of QUE (3.0, 9.0 and
15.0 mg/kg) exhibited this effect (Experiment 3; Figure 3). In the
challenge tests when all rats were injected with QUE, those who
had been treated with QUE previously did not make more or fewer
avoidance responses than those who had been treated with vehicle. This result was consistent across the 3 experiments, suggesting that prior QUE experience or treatment history did not cause a
long-term change in the behavioral sensitivity to QUE, regardless of
the route of drug administration. Thus, under the current test conditions, QUE does not appear to show a clozapine-like tolerance effect ( Feng et al., 2013b, Li et al., 2012, Li et al., 2010 and Qiao et al.,
2013), nor does it show an olanzapine-like sensitization effect ( Li
et al., 2009b, Li et al., 2010 and Swalve and Li, 2012), although they
all belong to the same atypical antipsychotic drug group.
As mentioned in Section 1, QUE’s avoidance disruptive effect
has been demonstrated before (Bjorkholm et al., 2013 and Wadenberg et al., 2001). Wadenberg et al. (2001) examined the relation
between striatal dopamine D2 occupancy and efficacy of avoidance
suppression. They found that QUE at 5, 10, 25, 50, 75 and 100 mg/
kg gave rise to a dose-dependent increase in striatal dopamine
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D2 occupancy in rats (58–81%) at the 1 h time point after injection. In the avoidance test, they found that QUE at 20 or 40 mg/kg
suppressed avoidance responding 20 min after injection. QUE at
40 mg/kg maintained its suppression even 90 min after administration. Bjorkholm et al. (2013) used an intravenous drug administration route and found that QUE at 6 and 9 mg/kg (i.v.) produced
a relatively transient suppression of avoidance 5 min after injection, but not after 30 min. In the present study, we also showed
that QUE at 9.0 and 15.0 mg/kg administered intravenously disrupted avoidance responding at 20 min post injection and this effect persisted throughout the 5-day testing period (Experiment 3).
One methodological difference between Bjorkholm et al. (2013)
and Experiment 3 was that we tested rats under the CS-only condition, while Bjorkholm et al. (2013) tested them under the CS–US
(shock) condition. This difference might explain why we observed
such a robust and severe suppression (reduced to ~20% avoidance
level), while Bjorkholm et al. (2013) only observed a mild suppression (reduced to ~50% level).
In comparison to other atypical antipsychotic drugs, such as
olanzapine, risperidone and clozapine, QUE displays a relatively
weak and short duration of action on avoidance responding. One
obvious reason is that QUE has a faster dissociation rate from dopamine D2 receptors and does not cause a sustained higher D2
occupancy (>80%) than other atypical drugs (Kapur and Seeman,
2000). The QUE 50 mg/kg (s.c.) tested in the present study only
produces 74% D2 occupancy (Wadenberg et al., 2001). Given that
D2 blockade is critical for antipsychotic action (Seeman, 2002) and
action in the CAR model (Wadenberg et al., 2001), it could be said
that QUE transiently disrupts avoidance behavior because it only
transiently blocks dopamine D2 receptors. The second possible
reason is that QUE does not produce norquetiapine in rodents
(Bjorkholm et al., 2013). Because norquetiapine has a potent inhibitory action against the norepinephrine transporter (NET) (Jensen
et al., 2008), and the NET inhibition by reboxetine (a selective NET
inhibitor) often enhances the avoidance–disruptive effect of QUE
(Bjorkholm et al., 2013), it is reasonable to suggest that norquetiapine could potentially enhance the avoidance–disruptive effect
of QUE. Therefore, lack of this metabolite in rats may contribute
to the overall weak effect of QUE.
In our previous studies of the motivational salience attenuation action of antipsychotics, we have shown that atypical antipsychotics (e.g. clozapine, olanzapine and risperidone) suppress
avoidance responses elicited by a less salient conditioned stimulus
(e.g. pure tone CS2 as it was only partially reinforced) to a greater
extent than avoidances elicited by a more salient stimulus (e.g.
white noise CS1 as it was reinforced in every trial), regardless of
the baseline difference in the number of CS1 and CS2 avoidances
( Li et al., 2009b, 2012; Zhang et al., 2011). The differential sensitivity to QUE (50 mg/kg) of CS1 and CS2 avoidance was not apparent
in our current experimental condition, although we did observe
that prior conditioning to CS1 renders CS2 less effective in eliciting an avoidance response (Figure 1 and Figure 2). Why QUE did
not show a preferential suppression of CS2 avoidance over CS1
avoidance is not entirely clear. Besides QUE’s relative weaker effect on avoidance than other atypicals, the procedural differences
between the present study and previous ones could be a factor. In
the previous studies, rats were trained in the CS1 and CS2 avoidance conditioning procedure first, and then tested in the same
procedure; while in the present study, rats were first trained in the
CS1 avoidance and then tested in the mixed CS1 and CS2 avoidance procedure. This issue will be further examined in the future
study to directly compare QUE with other atypical antipsychotics
in the same test procedure.
As mentioned before, our recent work on the long-term effects of repeated antipsychotic treatment has revealed two basic

behavioral patterns: sensitization and tolerance in the CAR model
and also in the phencyclidine-induced hyperlocomotion model
( Feng et al., 2013b, Gao and Li, 2013, Li et al., 2012, Mead and
Li, 2010, Qiao et al., 2013, Swalve and Li, 2012 and Zhang and Li,
2012). Specifically, we show that repeated administration of haloperidol, olanzapine or risperidone daily for 5–7 days tends to
cause a progressively increased inhibition of avoidance responding. When rats are given a challenge dose of these drugs at a later
point, they often make significantly fewer avoidance responses
than those that are treated with these drugs for the first time
( Li et al., 2009b, Li et al., 2010, Mead and Li, 2010, Qiao et al.,
2013, Swalve and Li, 2012 and Zhang and Li, 2012). Clozapine,
on the other hand, displays an opposite behavioral pattern (tolerance). During the daily drug test phase, repeated administration of clozapine causes no apparent sensitization or tolerance.
But on the challenge test, rats previously treated with clozapine
make significantly more avoidance responses than those that are
treated with clozapine for the first time (Feng et al., 2013b, Li et
al., 2010 and Qiao et al., 2013). QUE, very much like clozapine, has
high to moderate affinities for α1-adrenergic, 5-HT2A, H1 and low
affinities for D1, D2 and α2-adrenergic receptors (Jibson and Tandon, 1998; Miyamoto et al., 2005), and fast dissociation from the
D2 receptor ( Kapur and Seeman, 2000; Kapur et al., 2000). We
thus hypothesized that repeated treatment of QUE would cause a
clozapine-like tolerance effect in the CAR model. Results indicate
that although there was a trend for QUE tolerance, i.e. rats previously treated with QUE had higher avoidance than those previously treated with vehicle, the difference failed to reach a significant level based on the one-way ANOVA. Therefore, if QUE does
cause a clozapine-like tolerance effect, this effect may still be relatively weak. Because antipsychotic sensitization and tolerance are
modulated by various experimental parameters (e.g. drug doses,
number of drug administrations, test–retest intervals, etc.), more
studies are needed to further determine the features of QUE repeated treatment effect.
The clinical efficacy of QUE is similar to those of other atypical antipsychotic drugs. Its mechanism of action is also relatively
similar. Like other atypical drugs, the antipsychotic efficacy of QUE
in schizophrenia is thought to be mediated by its transient high
D2 blockade in the striatum (Kapur et al., 2000) or a combination
of dopamine D2 and serotonin 5-HT2 antagonisms in the cortical
and subcortical areas (Ichikawa et al., 2002). Even though both clozapine and QUE are well tolerated by the patients, they have different pharmacokinetics. For example, the elimination half-life of
QUE (approximately 6 h) is shorter than that of clozapine (more
than 10.2 h), and its active metabolites, e.g. norclozapine (10.2 h)
( Fang and Mosier, 2014; Guitton et al., 1999; Winter et al., 2008).
Therefore, although the present study did not find strong evidence
at the behavioral level linking QUE with other atypicals, especially
clozapine, its behavioral similarities with other atypicals should not
be dismissed. Indeed, in the phencyclidine-induced prepulse inhibition (PPI) of acoustic startle reflex test (Li et al., 2011), we found
that repeated administration of both QUE and clozapine similarly
maintained their improvement effect on phencyclidine-induced
PPI deficits. Future work directly comparing QUE with other atypicals in the CAR model as well as other behavioral tests of antipsychotic activity (e.g. phencyclidine-induced hyperlocomotion
model) may be able to reveal the behavioral mechanisms of action of QUE and its possible similarities and differences to other
drugs. Overall, the present findings suggest that quetiapine is capable of suppressing avoidance response and maintains its suppression over the treatment period, a profile shared by other atypical antipsychotic drugs. However, prior quetiapine treatment does
not cause a long-term change in drug sensitivity (i.e. sensitization
or tolerance), a peculiar feature deserving further investigation.
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